Seeldrayers P
Service de Neurologie, C.H.U. de Charleroi.
Rev Med Brux. 1999 Sep;20(4):A264-7.
Because of the demonstration for the first time of a measurable effect on magnetic resonance imaging, the publication in 1993 of the results of the American trial of interferon beta-1b in multiple sclerosis constituted a turning point in the history of multiple sclerosis (MS) treatment. Although many questions subsist concerning its optimal use, it has become a standard in the treatment of relapsing remitting MS to which new and old drugs will have to be compared. It seemed therefore meaningful to review the results obtained with recombinant interferon beta-1b and the more recently developed interferon beta-1a, and to place them in the context of the other immunomodulatory treatments currently offered in MS.
由于首次证明了对磁共振成像有可测量的效果，1993年美国关于β-1b干扰素治疗多发性硬化症试验结果的发表成为了多发性硬化症（MS）治疗史上的一个转折点。尽管关于其最佳使用仍存在许多问题，但它已成为复发缓解型MS治疗的标准，新老药物都必须与之进行比较。因此，回顾重组β-1b干扰素和最近开发的β-1a干扰素所取得的结果，并将它们置于目前MS中提供的其他免疫调节治疗的背景下，似乎是有意义的。
